Quest Diagnostics ROA 2010-2024 | DGX
Current and historical return on assets (ROA) values for Quest Diagnostics (DGX) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Quest Diagnostics ROA - Return on Assets Historical Data |
| Date |
TTM Net Income |
Total Assets |
Return on Assets |
| 2024-12-31 |
$0.87B |
$16.15B |
5.78% |
| 2024-09-30 |
$0.84B |
$16.10B |
5.78% |
| 2024-06-30 |
$0.84B |
$13.88B |
6.04% |
| 2024-03-31 |
$0.84B |
$13.95B |
6.14% |
| 2023-12-31 |
$0.85B |
$14.02B |
6.33% |
| 2023-09-30 |
$0.76B |
$13.48B |
5.77% |
| 2023-06-30 |
$0.79B |
$13.43B |
6.05% |
| 2023-03-31 |
$0.79B |
$12.79B |
6.05% |
| 2022-12-31 |
$0.94B |
$12.84B |
7.13% |
| 2022-09-30 |
$1.23B |
$13.22B |
9.16% |
| 2022-06-30 |
$1.48B |
$13.31B |
10.95% |
| 2022-03-31 |
$1.87B |
$13.44B |
14.01% |
| 2021-12-31 |
$1.99B |
$13.61B |
14.73% |
| 2021-09-30 |
$2.18B |
$13.57B |
16.02% |
| 2021-06-30 |
$2.24B |
$12.86B |
16.31% |
| 2021-03-31 |
$1.80B |
$13.93B |
13.03% |
| 2020-12-31 |
$1.43B |
$14.03B |
10.71% |
| 2020-09-30 |
$1.11B |
$14.14B |
8.50% |
| 2020-06-30 |
$0.75B |
$12.99B |
6.03% |
| 2020-03-31 |
$0.79B |
$12.05B |
6.52% |
| 2019-12-31 |
$0.86B |
$12.84B |
7.07% |
| 2019-09-30 |
$0.73B |
$12.02B |
6.27% |
| 2019-06-30 |
$0.73B |
$11.76B |
6.39% |
| 2019-03-31 |
$0.72B |
$11.94B |
6.47% |
| 2018-12-31 |
$0.74B |
$11.00B |
6.78% |
| 2018-09-30 |
$0.86B |
$10.99B |
8.04% |
| 2018-06-30 |
$0.81B |
$10.75B |
7.65% |
| 2018-03-31 |
$0.79B |
$10.70B |
7.51% |
| 2017-12-31 |
$0.77B |
$10.50B |
7.49% |
| 2017-09-30 |
$0.67B |
$10.44B |
6.57% |
| 2017-06-30 |
$0.70B |
$10.17B |
6.91% |
| 2017-03-31 |
$0.70B |
$10.11B |
6.94% |
| 2016-12-31 |
$0.64B |
$10.10B |
6.34% |
| 2016-09-30 |
$0.68B |
$10.17B |
6.69% |
| 2016-06-30 |
$0.83B |
$10.11B |
8.20% |
| 2016-03-31 |
$0.75B |
$10.10B |
7.51% |
| 2015-12-31 |
$0.71B |
$9.96B |
7.00% |
| 2015-09-30 |
$0.71B |
$10.07B |
7.06% |
| 2015-06-30 |
$0.50B |
$9.72B |
4.98% |
| 2015-03-31 |
$0.51B |
$10.61B |
5.13% |
| 2014-12-31 |
$0.56B |
$9.86B |
5.71% |
| 2014-09-30 |
$0.51B |
$9.80B |
5.35% |
| 2014-06-30 |
$0.79B |
$9.76B |
8.44% |
| 2014-03-31 |
$0.82B |
$9.55B |
8.96% |
| 2013-12-31 |
$0.85B |
$8.95B |
9.38% |
| 2013-09-30 |
$0.76B |
$8.93B |
8.34% |
| 2013-06-30 |
$0.52B |
$9.04B |
5.63% |
| 2013-03-31 |
$0.53B |
$9.31B |
5.72% |
| 2012-12-31 |
$0.56B |
$9.28B |
5.94% |
| 2012-09-30 |
$0.69B |
$9.32B |
7.36% |
| 2012-06-30 |
$0.70B |
$9.39B |
7.46% |
| 2012-03-31 |
$0.68B |
$9.45B |
7.29% |
| 2011-12-31 |
$0.47B |
$9.31B |
5.05% |
| 2011-09-30 |
$0.45B |
$9.33B |
4.90% |
| 2011-06-30 |
$0.47B |
$9.43B |
5.31% |
| 2011-03-31 |
$0.51B |
$9.23B |
5.82% |
| 2010-12-31 |
$0.72B |
$8.53B |
8.49% |
| 2010-09-30 |
$0.74B |
$8.46B |
8.67% |
| 2010-06-30 |
$0.73B |
$8.48B |
8.62% |
| 2010-03-31 |
$0.72B |
$8.52B |
8.60% |
| 2009-12-31 |
$0.73B |
$8.56B |
8.71% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$19.317B |
$9.872B |
|
Quest Diagnostics, Inc. is the provider of commercial laboratory services. Quest provides lab testing services to physicians, hospitals, managed care organizations, employers, government institutions and other clinical laboratories. The company consists of 2 business groups - Diagnostic Information Services and Diagnostic Solutions. The company's focus is on two elements - to accelerate growth and to drive operational excellence. Restore Growth: The company has adopted seven tactical approaches to accelerate growth such as sales and marketing; development of esoteric testing through a disease focus; partnerships with hospitals and successful testing of international IDNs; creation of value from information assets; leadership in companion diagnostics; extension into adjacent markets. Drive Operational excellence: The company plans to focus on four strategic requirements - to enhance end-to-end customer value chain, enterprise information technology architecture, business performance tools and cost excellence.
|
